Skip to content

Free 2-Day Air on orders $200+

Growth Hormone

CJC-1295 + Ipamorelin: Research Rationale and Evidence Limits

March 25, 2026 · 10 min read

Two powder-filled vials on a dark laboratory worktop.

CJC-1295 and ipamorelin are frequently discussed together in growth hormone research. Evidence about either compound, another GHRH/GHRP pairing or a different formulation does not by itself establish the response to a CJC-1295 no-DAC/ipamorelin blend.

This guide separates the research rationale from the evidence needed to assess a specific combination, including its exact materials, study model and measured outcomes.

The GHRH System: Where CJC-1295 Operates

Growth hormone-releasing hormone (GHRH) is the primary hypothalamic stimulator of GH synthesis and secretion. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylyl cyclase, increasing cAMP, and triggering both GH gene transcription and the secretory release of pre-formed GH granules. GHRH doesn't just prompt existing GH to be released; it drives the production of more.

22EXO's catalog distinguishes the CJC-1295 NO DAC / Mod GRF format from CJC-1295 DAC. A shared or abbreviated name is not enough to establish that the materials, modifications or experimental behavior are equivalent. Check which material a paper actually studied before applying its findings to a catalog item.

Teichman and colleagues' 2006 paper concerns CJC-1295 with DAC. Its findings should not be used to assign a half-life, acute peak response or combination effect to CJC-1295 without DAC, Mod GRF or a blend containing ipamorelin.

Ipamorelin: The Selective GHRP

Ipamorelin belongs to a different class entirely: growth hormone-releasing peptides (GHRPs). Rather than binding the GHRH receptor, GHRPs bind the GHS-R1a receptor (the ghrelin receptor), triggering GH release through a calcium-dependent mechanism that operates independently of the GHRH pathway. The two receptor systems are distinct; blocking one doesn't eliminate the other's GH-releasing activity.

Raun and colleagues at Novo Nordisk published the defining ipamorelin characterization study in the European Journal of Endocrinology in 1998, still the foundational reference for this compound. The paper described a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with GH-releasing potency and efficacy comparable to GHRP-6 in both in vitro pituitary cell assays and in vivo rat and swine models.

In anesthetized rats, ipamorelin's ED50 was 80 ± 42 nmol/kg with a maximal GH response (Emax) of 1,545 ± 250 ng GH/ml, comparable to GHRP-6 (ED50 = 115 ± 36 nmol/kg; Emax = 1,167 ± 120 ng GH/ml). In conscious swine, the ED50 was 2.3 ± 0.03 nmol/kg with an Emax of 65 ± 0.2 ng GH/ml, again essentially equivalent to GHRP-6's 3.9 ± 1.4 nmol/kg and 74 ± 7 ng GH/ml.

Potency roughly equivalent to GHRP-6. So why is ipamorelin considered superior? Because of what it doesn't do.

The Selectivity That Defines Ipamorelin

This is where Raun's 1998 paper gets genuinely interesting. Other GHRPs (GHRP-2 and GHRP-6 specifically) significantly elevate ACTH and cortisol levels when administered. These are stress hormones. Cortisol elevation is a common side effect concern with GHRPs, and it represents an off-target pharmacological effect that complicates interpretation of research results and creates physiological side effects that researchers want to avoid.

Ipamorelin showed essentially no effect on ACTH or cortisol in swine, even at doses more than 200-fold higher than the ED50 for GH release. Let that sink in. At 210 times the GH-effective dose, ipamorelin produced ACTH and cortisol plasma levels indistinguishable from those following GHRH stimulation. GHRP-6 at 85 times its GH ED50 and GHRP-2 at 45 times its GH ED50 both produced significant cortisol and ACTH responses.

The swine experiment in Raun and colleagues' study reported that none of the tested GH secretagogues affected plasma FSH, LH, prolactin or TSH. Those measured endpoints do not establish an absence of thyroid or gonadal disruption across other models or in humans. The authors' selectivity conclusion concerns the experimental conditions and hormone responses they measured.

Research Rationale and Combination Evidence

GH release from the pituitary is regulated by two opposing hormones: GHRH (stimulatory) and somatostatin (inhibitory). A GH pulse occurs when GHRH activity peaks while somatostatin tone is low. The timing matters: these two signals must align for robust GH release.

GHRPs like ipamorelin work through two mechanisms simultaneously: they activate GHS-R1a receptors to stimulate GH release, and they suppress somatostatin secretion, which removes the brake on GH release from the pituitary. GHRH analogs like CJC-1295 step on the accelerator. Ipamorelin both steps on the accelerator (via a different receptor) and releases the brake.

When both are present simultaneously:

  • GHRH receptor activation drives GH synthesis and secretion
  • GHS-R1a activation independently stimulates GH granule release
  • Somatostatin suppression removes the inhibitory counterweight

A complementary-receptor rationale is not proof of a larger or synergistic response from a particular blend. A combination claim requires evidence for the specific compounds, formulation, comparator and experimental model; studies of the individual compounds do not supply that comparison.

Comparing Published Study Designs

The clinical and research literature doesn't converge on a single universal ratio, but several patterns emerge. Teichman's CJC-1295 pharmacokinetic work used 30–250 μg/kg ranges. Raun's ipamorelin work used nmol/kg quantities in animal models. In human research contexts, many protocols have explored equimolar or near-equimolar GHRH/GHRP combinations.

Do not assume that the two components peak or clear together. A blend's pharmacokinetics and experimental effects require combination-specific evidence; separate compound descriptions and a NO DAC label do not establish matched half-lives or synchronized activity.

A ratio or administration schedule reported in one study is not a recommendation for another experiment or for personal use. Read the original protocol and retain its model, formulation and measurement limits when comparing findings.

What Research Goals Does This Combination Address?

The GHRH + GHRP combination is the most studied approach for GH axis stimulation in research contexts. Relevant research applications include:

  • Body composition studies (lean mass, fat oxidation, muscle protein synthesis) where IGF-1 elevation is the primary dependent variable
  • Recovery and tissue repair models where GH-mediated collagen synthesis and cellular regeneration are endpoints
  • Sleep quality research, given GH's role in slow-wave sleep architecture
  • Metabolic research examining GH's effects on insulin sensitivity and lipid metabolism
  • GH deficiency model investigations, where stimulating endogenous secretion (rather than replacing exogenous GH) is the experimental intervention

One advantage of the secretagogue approach over exogenous GH administration is that the pituitary remains in control of the output: there's a natural ceiling to how much GH can be secreted, because the pituitary has a finite reserve and the negative feedback system remains intact. Somatostatin release increases in response to elevated GH and IGF-1, providing auto-regulation that exogenous GH administration doesn't offer.

Available Research Formats

For laboratory research, 22EXO lists both pre-blended and individual formats. The CJC-1295 No-DAC + Ipamorelin Blend (5mg/5mg) and CJC-1295 No-DAC + Ipamorelin Blend (10mg/10mg) identify the quantity of each component in the vial. CJC-1295 No-DAC / Mod GRF (5mg) and Ipamorelin (5mg) are listed separately. These catalog formats do not establish a tested combination protocol or an administration schedule.

Distinguishing Ipamorelin from Other GHRPs

In Raun and colleagues' 1998 experiments, ipamorelin and GHRP-6 showed comparable potency and efficacy in the rat and swine models. GHRP-2 showed higher potency but a lower maximal GH response in the swine experiment. Potency, maximal response and hormone selectivity are different measurements; none establishes a universally superior compound for every research design.

Raun's animal selectivity experiments do not establish comparative human adverse-event rates, clinical tolerability or the safety of a CJC-1295/ipamorelin blend.

Frequently asked questions

What did Raun's study show about comparative potency and selectivity?

Raun and colleagues (1998) studied primary rat pituitary cells, anesthetized rats and conscious swine. Ipamorelin and GHRP-6 had comparable potency and efficacy; GHRP-2 had higher potency but a lower maximal GH response in the swine experiment. The hormone-selectivity findings concern those experimental models, not universal research superiority or comparative human safety.

What evidence is needed for a CJC-1295 and ipamorelin synergy claim?

A synergy claim requires combination-specific evidence identifying the exact compounds and formulation, the comparator, the experimental model and the measured response. A complementary-receptor rationale or separate studies of CJC-1295 and ipamorelin do not establish that a commercial blend produces a synergistic effect.

What is the difference between CJC-1295 No-DAC and CJC-1295 DAC in combination protocols?

Check the exact material and modification used in each paper. The CJC-1295 DAC findings in Teichman and colleagues' 2006 study should not be assigned to a no-DAC / Mod GRF product or to an ipamorelin blend. Do not assume matched half-lives, synchronized peaks or a preferred combination schedule from catalog names alone.

What did Raun et al. report about hormone responses in swine?

In Raun and colleagues' 1998 swine experiments, ipamorelin did not produce the ACTH and cortisol responses reported for GHRP-2 and GHRP-6 under the tested conditions. The study also reported no effect of the tested secretagogues on plasma FSH, LH, prolactin or TSH. These are measured animal-model endpoints, not a demonstration of human clinical safety.

Do animal selectivity findings establish the safety of a CJC-1295/ipamorelin blend?

No. Raun and colleagues' experiments concern ipamorelin and comparator secretagogues in rat and swine models. Those findings do not establish clinical tolerability, comparative human adverse-event rates or preserved feedback regulation for a CJC-1295/ipamorelin blend. Combination-specific evidence is needed for a combination claim.

Related products

This article is for educational purposes. Products referenced are for in-vitro laboratory research use only.